Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › AstraZeneca, Merck's Lynparza, Myriad Genetics' BRCA Test Approved in Japan

AstraZeneca, Merck's Lynparza, Myriad Genetics' BRCA Test Approved in Japan

Jun 19, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Japan's Pharmaceuticals and Medical Devices Agency has approved olaparib (Lynparza) as a first-line maintenance treatment after BRCA-mutated advanced ovarian cancer patients have responded to platinum-based chemotherapy.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Regulatory News & FDA Approvals

  1. Blueprint Medicines to Pursue Ayvakit Approval in Cancer-Causing Mast Cell Disorder

  2. Blueprint Medicine's Ayvakyt Garners Conditional European Commission Authorization in GIST

  3. EMA Committee Recommends Narrower Lynparza Indication for Metastatic Prostate Cancer Than FDA

  4. FDA Accepts Pfizer's sNDA for Xalkori in Rare ALK-Positive Pediatric Leukemia Indication

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.